TheMarker: a comprehensive database of therapeutic biomarkers.

Publisher: Oxford University Press Country of Publication: England NLM ID: 0411011 Publication Model: Print Cited Medium: Internet ISSN: 1362-4962 (Electronic) Linking ISSN: 03051048 NLM ISO Abbreviation: Nucleic Acids Res Subsets: MEDLINE

Publication: 1992- : Oxford : Oxford University Press
Original Publication: London, Information Retrieval ltd.

Biomarkers* ; Databases, Factual*; Humans ; Drug Discovery ; Therapeutics ; Prognosis ; Disease

Distinct from the traditional diagnostic/prognostic biomarker (adopted as the indicator of disease state/process), the therapeutic biomarker (ThMAR) has emerged to be very crucial in the clinical development and clinical practice of all therapies. There are five types of ThMAR that have been found to play indispensable roles in various stages of drug discovery, such as: Pharmacodynamic Biomarker essential for guaranteeing the pharmacological effects of a therapy, Safety Biomarker critical for assessing the extent or likelihood of therapy-induced toxicity, Monitoring Biomarker indispensable for guiding clinical management by serially measuring patients' status, Predictive Biomarker crucial for maximizing the clinical outcome of a therapy for specific individuals, and Surrogate Endpoint fundamental for accelerating the approval of a therapy. However, these data of ThMARs has not been comprehensively described by any of the existing databases. Herein, a database, named 'TheMarker', was therefore constructed to (a) systematically offer all five types of ThMAR used at different stages of drug development, (b) comprehensively describe ThMAR information for the largest number of drugs among available databases, (c) extensively cover the widest disease classes by not just focusing on anticancer therapies. These data in TheMarker are expected to have great implication and significant impact on drug discovery and clinical practice, and it is freely accessible without any login requirement at: https://idrblab.org/themarker.
(© The Author(s) 2023. Published by Oxford University Press on behalf of Nucleic Acids Research.)

Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. (PMID: 36243960)
Nat Rev Gastroenterol Hepatol. 2020 Nov;17(11):702-710. (PMID: 32879465)
ACS Chem Neurosci. 2022 Feb 2;13(3):340-351. (PMID: 35041375)
Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5. (PMID: 23193258)
Comput Biol Med. 2022 Jun;145:105465. (PMID: 35366467)
Brief Bioinform. 2020 May 21;21(3):1058-1068. (PMID: 31157371)
Clin Pharmacol Ther. 2021 Aug;110(2):346-360. (PMID: 33559152)
Genomics Proteomics Bioinformatics. 2023 Jun;21(3):535-550. (PMID: 36775056)
Nucleic Acids Res. 2021 Jan 8;49(D1):D1233-D1243. (PMID: 33045737)
Clin Cancer Res. 2022 Apr 1;28(7):1422-1432. (PMID: 35078858)
Bioinformatics. 2021 Dec 7;37(23):4534-4539. (PMID: 34164644)
Toxicol Sci. 2018 Sep 1;165(1):100-107. (PMID: 29788510)
Nat Rev Rheumatol. 2020 Aug;16(8):448-463. (PMID: 32606474)
Lancet Diabetes Endocrinol. 2019 Feb;7(2):128-139. (PMID: 30635226)
Neurooncol Adv. 2023 May 11;5(1):vdad061. (PMID: 37313502)
J Hematol Oncol. 2021 Sep 23;14(1):151. (PMID: 34556161)
JAMA. 2017 Mar 14;317(10):1017-1018. (PMID: 28125758)
Int J Biol Macromol. 2021 Mar 31;174:263-269. (PMID: 33529633)
ACS Med Chem Lett. 2020 Mar 06;11(4):403-406. (PMID: 32292539)
Nucleic Acids Res. 2022 Jan 7;50(D1):D560-D570. (PMID: 34664670)
Proc Natl Acad Sci U S A. 2020 May 5;117(18):9952-9963. (PMID: 32345717)
Comput Biol Med. 2023 Feb;153:106464. (PMID: 36584603)
Database (Oxford). 2022 Jul 5;2022:. (PMID: 35788654)
Lancet. 2021 Mar 13;397(10278):1010-1022. (PMID: 33285141)
PLoS Med. 2019 Sep 10;16(9):e1002873. (PMID: 31504034)
Database (Oxford). 2021 Mar 9;2021:. (PMID: 33693668)
JAMA. 2023 Apr 11;329(14):1160-1169. (PMID: 37039792)
BMC Med Genomics. 2021 Apr 19;14(1):109. (PMID: 33874942)
Database (Oxford). 2019 Jan 1;2019:. (PMID: 31169290)
Ann Oncol. 2022 Dec;33(12):1304-1317. (PMID: 36055464)
Expert Opin Drug Discov. 2021 Nov;16(11):1365-1390. (PMID: 34181496)
Expert Rev Mol Diagn. 2018 Jun;18(6):513-529. (PMID: 29701114)
Nat Rev Drug Discov. 2021 Jan;20(1):64-81. (PMID: 33199880)
J Hematol Oncol. 2021 Aug 21;14(1):128. (PMID: 34419139)
Nucleic Acids Res. 2020 Jan 8;48(D1):D908-D912. (PMID: 31724701)
Nat Protoc. 2022 Jan;17(1):129-151. (PMID: 34952956)
Bioinformatics. 2004 Feb 12;20(3):307-15. (PMID: 14960456)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
J Immunother Cancer. 2019 Feb 20;7(1):50. (PMID: 30786924)
Nucleic Acids Res. 2021 Jan 8;49(D1):D1251-D1258. (PMID: 33219685)
BMJ. 2022 Jul 29;378:o1912. (PMID: 35905986)
ACS Chem Neurosci. 2018 May 16;9(5):1128-1140. (PMID: 29300091)
Brief Bioinform. 2021 May 20;22(3):. (PMID: 32591816)
Comput Struct Biotechnol J. 2022 Mar 10;20:1295-1305. (PMID: 35356542)
Front Genet. 2020 Oct 06;11:907. (PMID: 33133126)
Nucleic Acids Res. 2023 Jan 6;51(D1):D546-D556. (PMID: 36200814)
Bioinformatics. 2010 Oct 1;26(19):2363-7. (PMID: 20688976)
Front Med (Lausanne). 2022 Feb 18;9:820990. (PMID: 35252258)
Transl Oncol. 2021 Jun;14(6):101063. (PMID: 33714919)
Lancet. 2019 Jul 27;394(10195):281-283. (PMID: 31354129)
Cancer Treat Rev. 2019 Jul;77:57-66. (PMID: 31279169)
Genome Biol. 2017 Aug 11;18(1):153. (PMID: 28800781)
Brief Bioinform. 2022 Mar 10;23(2):. (PMID: 35183059)
Front Oncol. 2022 Aug 11;12:792055. (PMID: 36081550)
Ann Oncol. 2020 Dec;31(12):1603-1605. (PMID: 33011228)
J Proteomics. 2021 Feb 10;232:104023. (PMID: 33130111)
Nat Rev Drug Discov. 2023 Apr;22(4):317-335. (PMID: 36781957)
PLoS Comput Biol. 2020 Jan 22;16(1):e1007607. (PMID: 31967990)
Brief Bioinform. 2020 Mar 23;21(2):621-636. (PMID: 30649171)
Front Pharmacol. 2023 May 02;14:1096366. (PMID: 37201021)
Lancet. 2021 Apr 17;397(10283):1496-1504. (PMID: 33773610)
J Am Acad Dermatol. 2020 Apr;82(4):854-861. (PMID: 31449902)
Nucleic Acids Res. 2022 Jan 7;50(D1):D1184-D1199. (PMID: 34570230)
Brief Bioinform. 2020 Mar 23;21(2):649-662. (PMID: 30689717)
Am J Hematol. 2008 Jan;83(1):59-62. (PMID: 17712791)
Nucleic Acids Res. 2020 Jul 2;48(W1):W436-W448. (PMID: 32324219)
J Immunother Cancer. 2022 Mar;10(3):. (PMID: 35292517)
J Toxicol Sci. 2019;44(4):225-235. (PMID: 30944276)
Int J Infect Dis. 2017 Mar;56:253-257. (PMID: 28159577)
Cancers (Basel). 2021 Feb 20;13(4):. (PMID: 33672646)
Science. 2022 Aug 19;377(6608):818-819. (PMID: 35981039)
Brief Bioinform. 2022 May 13;23(3):. (PMID: 35368077)
Nucleic Acids Res. 2017 Jul 3;45(W1):W162-W170. (PMID: 28525573)
Nat Rev Drug Discov. 2022 Jul;21(7):495-508. (PMID: 34316029)
Brief Bioinform. 2022 Jan 17;23(1):. (PMID: 34585235)
Trends Pharmacol Sci. 2019 Sep;40(9):624-635. (PMID: 31383376)
Radiat Res. 2018 Nov;190(5):513-525. (PMID: 30117783)
Front Genet. 2019 Sep 18;10:830. (PMID: 31620162)
Neuropsychopharmacology. 2022 Jun;47(7):1405-1412. (PMID: 34675381)
Proc Natl Acad Sci U S A. 2023 Apr 25;120(17):e2218522120. (PMID: 37068243)
Nucleic Acids Res. 2021 Jan 8;49(D1):D1259-D1267. (PMID: 33245771)
Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22020-22029. (PMID: 31548386)
Semin Cancer Biol. 2022 Feb;79:4-17. (PMID: 33819567)
Bioinformatics. 2003 Jan 22;19(2):185-93. (PMID: 12538238)
Nucleic Acids Res. 2020 Jan 8;48(D1):D77-D83. (PMID: 31665515)
Neuro Oncol. 2018 Aug 2;20(9):1162-1172. (PMID: 29294069)
Adv Sci (Weinh). 2023 May;10(15):e2207061. (PMID: 36950745)
Cell. 2020 Oct 1;183(1):269-283.e19. (PMID: 32916130)
Nucleic Acids Res. 2020 Jan 8;48(D1):D1042-D1050. (PMID: 31495872)
Database (Oxford). 2023 Feb 7;2023:. (PMID: 36747479)
Nat Rev Neurol. 2020 Jul;16(7):381-400. (PMID: 32541893)
Nat Rev Nephrol. 2018 Jun;14(6):378-393. (PMID: 29626199)
Nucleic Acids Res. 2018 Jan 4;46(D1):D1128-D1136. (PMID: 30053270)
Nucleic Acids Res. 2022 Jan 7;50(D1):D1417-D1431. (PMID: 34747471)
Nucleic Acids Res. 2023 Jan 6;51(D1):D1288-D1299. (PMID: 36243961)
Database (Oxford). 2019 Jan 1;2019:. (PMID: 31260040)

82373790 National Natural Science Foundation of China; LR21H300001 Natural Science Foundation of Zhejiang Province; 2022YFC3400501 National Key R&D Program of China; Leading Talent of the 'Ten Thousand Plan' National High-Level Talents Special Support Plan of China; 181201*194232101 The Double Top-Class Universities; 2018QNA7023 Fundamental Research Funds for Central Universities; 2020C03010 Key R&D Program of Zhejiang Province; Westlake Laboratory; Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare; Alibaba Cloud; Zhejiang University

0 (Biomarkers)

Date Created: 20231018 Date Completed: 20240119 Latest Revision: 20240119

20240119

PMC10767989

10.1093/nar/gkad862

37850638